Herbal Medicines as Alternatives to Synthetic Drugs: Scientific Evidence, Pharmacological Validity, and Translational Challenges in Modern Therapeutics

Lukas Matthias Schneider [1*], Hannah Elise Wagner [2], Jonas Friedrich Keller [3], Clara Sophie Brandt [4], Maximilian Otto Reinhardt [5]

[1] PhD, Institute for Pharmaceutical Technology and Biopharmaceutics, University of Heidelberg, Germany
[2] PhD, Department of Nanomedicine and Biomaterials, Technical University of Munich, Germany
[3] PhD, Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt, Germany
[4] PhD, Institute of Pharmaceutical Sciences, University of Freiburg, Germany
[5] PhD, Department of Targeted Drug Delivery Systems, Charité–Universitätsmedizin Berlin, Germany

* Corresponding Author: **Lukas Matthias Schneider**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 01
January – February 2024
Received: 09-11-2023
Accepted: 11-12-2023
Published: 13-01-2024
Page No: 32-38

Abstract
Herbal medicines represent a pharmacologically diverse class of therapeutics that have gained renewed scientific interest as potential alternatives or adjuncts to conventional synthetic drugs. Unlike traditional ethnopharmacological narratives, contemporary research emphasizes evidence-based characterization of bioactive phytochemicals, elucidation of molecular mechanisms, and rigorous clinical validation. This review critically examines the pharmacological basis, therapeutic applications, and translational challenges of herbal medicines within the framework of modern pharmaceutical sciences. Key herbal drug classes including cardiovascular agents, anti-inflammatory compounds, neuroprotective phytochemicals, and antimicrobial botanicals are analyzed with emphasis on their pharmacodynamic properties, target engagement, and mechanistic pathways. Comparative assessment reveals that certain standardized herbal preparations demonstrate efficacy profiles comparable to synthetic drugs while potentially offering advantages in multi-target modulation, synergistic effects, and tolerability. However, significant challenges persist regarding standardization, pharmacokinetic variability, drug-herb interactions, regulatory classification, and the paucity of robust head-to-head clinical trials. The translational pathway from traditional use to evidence-based medicine requires integration of advanced analytical techniques, pharmacokinetic modeling, systems pharmacology approaches, and adherence to stringent regulatory frameworks. This review synthesizes current scientific evidence supporting herbal medicines as viable therapeutic alternatives, identifies critical knowledge gaps, and proposes strategies for their rational integration into contemporary clinical practice.

DOI: https://doi.org/10.54660/IJPIS.2024.1.1.32-38

Keywords: herbal medicines, phytopharmaceuticals, evidence-based therapeutics, comparative pharmacology, drug standardization, translational medicine

1. Introduction

The development of synthetic pharmaceuticals in the 20th century revolutionized therapeutic medicine, enabling targeted intervention in disease pathophysiology with unprecedented precision [1]. However, limitations of synthetic drugs including adverse effects, narrow therapeutic indices, development costs, and emerging resistance patterns have prompted renewed interest in alternative therapeutic modalities [2, 3]. Herbal medicines, defined as standardized plant-derived preparations containing

pharmacologically active constituents, represent a scientifically viable alternative paradigm when subjected to rigorous pharmaceutical evaluation [4].

Contemporary herbal pharmacology differs fundamentally from traditional medicine practices by emphasizing molecular characterization, mechanistic validation, and clinical evidence generation [5]. Approximately 25-50% of currently used synthetic drugs are derived from or inspired by natural products, demonstrating the pharmaceutical relevance of plant-based bioactive compounds [6]. Modern analytical technologies including high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy enable precise identification and quantification of active constituents, addressing historical concerns regarding compositional variability [7].

The pharmacological rationale for herbal medicines as alternatives to synthetic drugs rests on several key principles. First, many phytochemicals demonstrate validated interactions with established drug targets including receptors, enzymes, ion channels, and transporters [8]. Second, multi-component herbal preparations may exhibit synergistic or additive effects through simultaneous modulation of multiple pathways, potentially offering advantages over single-target synthetic drugs [9]. Third, certain herbal medicines demonstrate favorable safety profiles with reduced incidence of serious adverse events compared to synthetic alternatives in specific therapeutic contexts [10].

This review examines herbal medicines through the lens of evidence-based pharmaceutical science, focusing on experimentally validated mechanisms, comparative clinical efficacy, and translational implementation challenges. The objective is to critically assess the scientific basis for positioning standardized herbal preparations as legitimate therapeutic alternatives within modern medical practice.

2. Pharmacological Basis of Herbal Medicines

2.1. Molecular Mechanisms and Target Engagement

The therapeutic activity of herbal medicines derives from bioactive phytochemicals that interact with specific molecular targets through mechanisms analogous to synthetic drugs [11]. Major classes of pharmacologically active compounds include alkaloids, flavonoids, terpenoids, phenolic acids, and saponins, each demonstrating distinct pharmacodynamic properties [12].

Alkaloids such as berberine exhibit multi-target effects including AMP-activated protein kinase activation, which mediates glucose and lipid metabolism comparable to metformin [13]. Flavonoids including quercetin and epigallocatechin gallate demonstrate anti-inflammatory activity through inhibition of nuclear factor-κB signaling and cyclooxygenase enzymes [14]. Terpenoid compounds such as artemisinin derivatives show antimalarial efficacy through generation of reactive oxygen species and heme alkylation within parasites [15].

Mechanistic studies employing molecular docking, enzyme kinetics, and receptor binding assays have validated direct interactions between phytochemicals and therapeutic targets [16]. For instance, silymarin components bind to hepatocyte membrane receptors and inhibit toxin uptake while stimulating ribosomal RNA polymerase, demonstrating hepatoprotective mechanisms distinct from synthetic drugs [17].

2.2. Multi-Component Synergy and Systems Pharmacology

A distinguishing feature of herbal medicines is the presence of multiple bioactive constituents that may produce synergistic, additive, or potentiating effects [18]. Network pharmacology approaches have revealed that herbal preparations often modulate multiple nodes within disease-relevant biological networks, contrasting with the single-target paradigm of synthetic drugs [19].

The concept of phytochemical synergy is exemplified by cannabis-derived preparations where cannabidiol enhances the therapeutic effects of tetrahydrocannabinol while mitigating adverse psychoactive effects [20]. Similarly, combination of curcuminoids with piperine increases bioavailability through inhibition of hepatic and intestinal glucuronidation, enhancing anti-inflammatory efficacy [21].

Systems pharmacology modeling has identified that multi-component formulations may achieve therapeutic effects through redundant pathway targeting, compensatory mechanism engagement, and broader therapeutic windows compared to single compounds [22]. This polypharmaco logical profile may confer advantages in complex diseases involving multiple pathophysiological mechanisms.

2.3. Pharmacokinetic Considerations

Understanding absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties is essential for rational use of herbal medicines [23]. Many phytochemicals exhibit poor oral bioavailability due to extensive first-pass metabolism, efflux transporter activity, and limited aqueous solubility [24].

Pharmacokinetic studies demonstrate significant inter-individual variability in herbal medicine disposition, influenced by genetic polymorphisms in metabolizing enzymes, gut microbiome composition, and co-administered substances [25]. For instance, genetic variants of CYP2D6 and CYP3A4 significantly affect metabolism of alkaloids and flavonoids, necessitating consideration of pharmacogenetic factors [26].

Advanced formulation strategies including nanoencapsulation, phytosome technology, and standardized extraction methods have improved bioavailability and pharmacokinetic consistency of herbal preparations [27].

These pharmaceutical innovations are essential for achieving reproducible therapeutic outcomes comparable to synthetic drugs.

3. Evidence-Based Therapeutic Applications

3.1. Cardiovascular Therapeutics

Several herbal medicines demonstrate clinically validated cardiovascular effects with mechanisms comparable to synthetic drugs [28]. Hawthorn (*Crataegus* species) preparations exhibit positive inotropic and vasodilatory effects through inhibition of phosphodiesterase and angiotensin-converting enzyme, demonstrating efficacy in mild-to-moderate heart failure comparable to low-dose ACE inhibitors in controlled trials [29].

Garlic (*Allium sativum*) standardized extracts reduce blood pressure and lipid levels through hydrogen sulfide-mediated vasodilation and HMG-CoA reductase inhibition, with meta-

analyses showing modest but significant effects approaching those of low-dose statins [30]. Red yeast rice containing naturally occurring lovastatin demonstrates lipid-lowering efficacy equivalent to low-dose synthetic statins while potentially offering improved tolerability profiles [31].

3.2. Central Nervous System Applications

Phytopharmaceuticals targeting neurological and psychiatric conditions represent a growing area of clinical interest [32]. Hyperforin and hypericin from *Hypericum perforatum* (St. John's wort) inhibit monoamine reuptake and modulate GABA receptors, demonstrating efficacy in mild-to-moderate depression comparable to selective serotonin reuptake inhibitors in systematic reviews [33].

Standardized *Ginkgo biloba* extract EGb 761 exhibits neuroprotective effects through free radical scavenging, mitochondrial stabilization, and improved cerebral blood flow, showing modest cognitive benefits in dementia with effect sizes comparable to approved synthetic drugs like donepezil [34]. Bacosides from *Bacopa monnieri* enhance synaptic transmission and neuronal proliferation, demonstrating memory-enhancing effects validated in controlled clinical trials [35].

3.3. Anti-Inflammatory and Immunomodulatory Agents

Herbal anti-inflammatory agents offer mechanistically distinct alternatives to non-steroidal anti-inflammatory drugs and corticosteroids [36]. Curcumin demonstrates multi-pathway anti-inflammatory activity through NF-κB inhibition, COX-2 suppression, and modulation of inflammatory cytokines, showing clinical efficacy in osteoarthritis comparable to ibuprofen with superior gastrointestinal safety profiles [37].

Boswellic acids from *Boswellia serrata* inhibit 5-lipoxygenase and pro-inflammatory cytokines, demonstrating clinical benefits in rheumatoid arthritis and inflammatory bowel disease with mechanisms distinct from conventional immunosuppressants [38]. Resveratrol exhibits SIRT1 activation and anti-inflammatory signaling modulation, showing promise in metabolic and cardiovascular inflammation [39].

3.4. Antimicrobial Applications

Plant-derived antimicrobials represent potential alternatives amid rising antibiotic resistance [40]. Berberine demonstrates broad-spectrum antibacterial activity through disruption of bacterial cell division and DNA synthesis, with efficacy against resistant strains including MRSA [41]. Essential oils containing thymol and carvacrol exhibit membrane-disrupting antimicrobial activity with low resistance development potential [42].

Artemisinin combination therapies remain first-line treatment for uncomplicated malaria, demonstrating superior efficacy compared to previous synthetic antimalarials [43]. This represents the most successful translation of an herbal medicine into mainstream pharmaceutical practice.

4. Comparison with Synthetic Drugs

4.1. Efficacy and Therapeutic Outcomes

Direct comparative trials between standardized herbal preparations and synthetic drugs reveal variable efficacy profiles dependent on condition severity, patient population, and outcome measures [44]. For mild-to-moderate conditions, certain herbal medicines demonstrate non-inferior efficacy. Meta-analyses of St. John's wort versus SSRIs show equivalent response rates in mild-to-moderate depression, while hawthorn preparations produce comparable improvements in heart failure symptoms to low-dose ACE inhibitors [45].

However, for severe or acute conditions, synthetic drugs generally demonstrate superior efficacy and more rapid onset of action. The modest effect sizes of many herbal medicines limit their utility as monotherapy in advanced disease states, positioning them more appropriately as adjunctive or preventive interventions.

4.2. Safety and Tolerability Profiles

A frequently cited advantage of herbal medicines is improved tolerability compared to synthetic drugs. Clinical trials demonstrate lower incidence of certain adverse effects for herbal alternatives. St. John's wort shows reduced sexual dysfunction and weight gain compared to SSRIs, while curcumin demonstrates superior gastrointestinal safety versus NSAIDs.

However, the perception of herbal medicines as universally safe is problematic. Hepatotoxicity associated with *Piper methysticum* (kava), pyrrolizidine alkaloid toxicity from *Symphytum* species, and aristolochic acid nephropathy demonstrate serious safety concerns requiring vigilant pharmacovigilance. Drug-herb interactions, particularly with CYP3A4 and P-glycoprotein substrates, pose significant safety challenges.

4.3. Cost-Effectiveness and Accessibility

Economic analyses suggest potential cost advantages of herbal medicines, particularly in resource-limited settings. Lower development costs and generic availability of standardized extracts may improve therapeutic accessibility. However, quality standardization and regulatory compliance increase production costs, potentially negating economic advantages for pharmaceutical-grade preparations.

5. Clinical, Regulatory, and Translational Challenges

5.1. Standardization and Quality Control

The fundamental challenge in positioning herbal medicines as therapeutic alternatives is ensuring batch-to-batch consistency and bioequivalence. Phytochemical composition varies with botanical source, growing conditions, harvest timing, and processing methods. Implementation of Good Agricultural and Collection Practices (GACP) and pharmaceutical quality standards is essential but inconsistently applied globally.

Marker compound standardization, while useful, may inadequately capture the pharmacological complexity of multi-component preparations. Development of phytochemical fingerprinting using advanced analytical platforms and correlation with biological activity through quality-by-design approaches represents current best practice.

5.2. Clinical Evidence Gaps

Despite thousands of clinical studies, high-quality evidence for many herbal medicines remains limited. Common methodological limitations include small sample sizes,

inadequate blinding, lack of active comparators, and short follow-up periods. Systematic reviews frequently conclude that evidence is insufficient to recommend herbal medicines as first-line alternatives to synthetic drugs.

The complexity and cost of conducting large-scale, long-term comparative effectiveness trials for herbal medicines pose significant barriers. Patent limitations and commercial incentives differ substantially from synthetic drug development, reducing pharmaceutical industry investment in rigorous clinical validation.

5.3. Regulatory Frameworks

Regulatory classification of herbal medicines varies internationally, creating challenges for global therapeutic integration. European Medicines Agency herbal monographs, U.S. FDA dietary supplement regulations, and traditional medicine provisions in various jurisdictions reflect divergent approaches to evidence requirements and marketing authorization.

The traditional use registration pathway accepts historical use as evidence, while well-established use and full marketing authorization require increasing levels of pharmacological and clinical data. Harmonization of regulatory standards and evidence requirements is essential for legitimate positioning of herbal medicines as pharmaceutical alternatives.

5.4. Drug-Herb Interactions

Pharmacokinetic and pharmacodynamic interactions between herbal medicines and synthetic drugs represent significant clinical safety concerns. Induction or inhibition of cytochrome P450 enzymes and drug transporters by phytochemicals can substantially alter plasma concentrations of co-administered drugs.

St. John's wort induces CYP3A4 and P-glycoprotein, reducing efficacy of oral contraceptives, immunosuppressants, and antiretrovirals. Warfarin interactions with numerous herbal products necessitate careful monitoring and patient counseling. Comprehensive interaction databases and routine inquiry about herbal medicine use are essential clinical safety measures.

6. Future Perspectives

6.1. Integrated Approaches and Precision Medicine

Future therapeutic integration of herbal medicines will likely emphasize personalized approaches guided by pharmacogenomics, metabolomics, and systems biology. Identification of patient subpopulations most likely to respond to specific herbal preparations based on genetic variants, microbiome composition, and disease endotypes represents a promising direction.

Combination strategies integrating herbal and synthetic drugs to achieve synergistic effects or reduce adverse events warrant systematic investigation. Rational polypharmacy approaches informed by network pharmacology could optimize therapeutic outcomes while minimizing toxicity.

6.2. Advanced Drug Delivery and Formulation

Nanotechnology applications including liposomes, solid lipid nanoparticles, and polymer conjugates offer solutions to bioavailability limitations of hydrophobic phytochemicals. Targeted delivery systems could enhance tissue-specific accumulation and reduce systemic exposure, improving therapeutic indices.

Development of standardized, pharmaceutical-grade formulations with validated pharmacokinetic properties will be essential for positioning herbal medicines as legitimate alternatives in evidence-based practice.

6.3. Phytopharmaceutical Drug Discovery

Herbal medicines continue to serve as sources for new drug discovery, with active constituent isolation, structural modification, and semi-synthetic derivative development yielding improved pharmacological properties. The artemisinin story demonstrates successful translation from traditional use to isolated active principle to global therapeutic standard.

High-throughput screening of phytochemical libraries combined with computational target prediction accelerates identification of novel therapeutic candidates. Integration of traditional knowledge with modern drug discovery platforms represents a productive synergy.

7. Tables

Table 1: Advantages, Limitations, and Clinical Challenges of Herbal Medicines Compared with Synthetic Drugs

Aspect	Herbal Medicines	Synthetic Drugs	Clinical Implications
Target Selectivity	Multi-target modulation; network effects [18]	Single-target specificity; high selectivity [1]	Herbal medicines may address complex diseases; synthetic drugs offer precision [44]
Pharmacological Mechanism	Synergistic/additive effects from multiple constituents [9]	Defined mechanism via specific receptor/enzyme [11]	Herbal medicines require systems pharmacology validation; synthetic drugs have established pathways [16]
Bioavailability	Often poor; variable absorption and metabolism [24]	Optimized through medicinal chemistry [23]	Herbal medicines need formulation enhancement; synthetic drugs show consistent pharmacokinetics [27]
Standardization	Compositional variability; batch inconsistency [52]	Precise chemical composition; reproducible synthesis [53]	Herbal medicines require rigorous quality control; synthetic drugs meet pharmaceutical standards consistently [54]
Clinical Evidence	Limited high-quality RCTs; heterogeneous data [55]	Extensive phase I-IV trials; regulatory requirements [46]	Herbal medicines lack robust comparative trials; synthetic drugs have well-established efficacy profiles [56]
Safety Profile	Generally favorable for mild conditions; herb-drug interactions [47, 50]	Well-characterized adverse effects; predictable toxicity [2]	Herbal medicines may offer better tolerability; require interaction monitoring [61]
Regulatory Status	Variable classification; traditional use pathways [58, 59]	Stringent approval processes; marketing authorization [60]	Herbal medicines face regulatory heterogeneity; synthetic drugs follow standardized pathways [58]
Cost	Lower development costs; accessibility in resource-limited settings [51]	High R&D investment; patent protection [3]	Herbal medicines potentially more affordable; quality standardization increases costs [51]
Development Timeline	Shorter pathway for traditional use registration [60]	10-15 years from discovery to approval [3]	Herbal medicines faster to market via traditional pathways; synthetic drugs require extensive validation [57]
Resistance Development	Lower resistance potential for antimicrobials (multi-component) [42]	Common in antimicrobials and anticancer agents [40]	Herbal antimicrobials may reduce resistance; requires validation [43]

8. Figures



Fig 1: Comparative Framework of Herbal Medicines versus Synthetic Drugs in Therapeutic Development



Fig 2: Translational Pathway of Evidence-Based Herbal Medicines into Modern Clinical Practice

9. Conclusion

Herbal medicines represent pharmacologically valid therapeutic alternatives to synthetic drugs when subjected to rigorous scientific evaluation and pharmaceutical standardization. Evidence-based assessment reveals that standardized preparations of specific herbs demonstrate clinically meaningful efficacy in selected indications, particularly mild-to-moderate conditions where multi-target modulation and favorable tolerability profiles offer advantages. However, positioning herbal medicines as legitimate alternatives requires addressing fundamental challenges in standardization, clinical evidence generation, regulatory harmonization, and safety profiling.

The translational pathway from traditional use to evidence-based medicine demands integration of advanced analytical chemistry, mechanistic pharmacology, rigorous clinical trial methodology, and adherence to pharmaceutical quality standards. Neither uncritical acceptance based on traditional use nor dismissal due to complexity serves the advancement of therapeutics. Rather, a scientifically grounded approach recognizing both the potential and limitations of herbal medicines enables their rational integration into contemporary clinical practice.

Future progress depends on sustained investment in comparative effectiveness research, development of predictive biomarkers for treatment response, implementation of global quality standards, and cultivation of interdisciplinary expertise bridging traditional knowledge and pharmaceutical sciences. When appropriately validated and standardized, herbal medicines can complement the therapeutic armamentarium, offering patients and clinicians evidence-based alternatives that expand treatment options while maintaining the principles of modern pharmaceutical practice.

References

1. Drews J. Drug discovery: a historical perspective. Science. 2000;287(5460):1960-1964.
2. Grayson M. Adverse drug reactions. Nature. 2012;484(7395):S1.
3. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33.
4. World Health Organization. WHO Guidelines on Good Herbal Processing Practices for Herbal Medicines. Geneva: WHO; 2018.
5. Cordell GA, Colvard MD. Natural products and traditional medicine: turning on a paradigm. J Nat Prod. 2012;75(3):514-525.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.
7. Wolfender JL, Nuzillard JM, van der Hooft JJJ, *et al*. Accelerating metabolite identification in natural product research: toward an ideal combination of liquid chromatography-high-resolution tandem mass spectrometry and NMR profiling, in silico databases, and chemometrics. Anal Chem. 2019;91(1):704-742.
8. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.
9. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep. 2019;36(6):869-888.
10. Zhou X, Seto SW, Chang D, *et al*. Synergistic effects of Chinese herbal medicine: a comprehensive review of methodology and current research. Front Pharmacol. 2016;7:201.
11. Gertsch J. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med. 2011;77(11):1086-1098.
12. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, *et al*. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614.
13. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717.
14. Chirumbolo S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets. 2010;9(4):263-285.
15. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008;29(10):520-527.
16. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110-120.
17. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423-1432.
18. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97-110.
19. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
20. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.
21. Shoba G, Joy D, Joseph T, *et al*. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356.
22. Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110-1111.
23. Yang Y, Zhang Z, Li S, *et al*. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia. 2014;92:133-147.
24. Manach C, Williamson G, Morand C, *et al*. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81(1 Suppl):230S-242S.
25. Qiang Z, Ye Z, Hauck C, *et al*. Role of the gut microbiota in the pharmacokinetics of natural products. Curr Drug Metab. 2011;12(4):398-410.
26. Zhou SF, Xue CC, Yu XQ, *et al*. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.
27. Patra JK, Das G, Fraceto LF, *et al*. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
28. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55(6):515-525.
29. Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev. 2008;(1):CD005312.

30. Ried K, Frank OR, Stocks NP, *et al*. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2008;8:13.
31. Gerards MC, Terlou RJ, Yu H, *et al*. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-423.
32. Sarris J, Panossian A, Schweitzer I, *et al*. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21(12):841-860.
33. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;(4):CD000448.
34. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120.
35. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, *et al*. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-535.
36. Maroon JC, Bost JW, Maroon A. Natural anti-inflammatory agents for pain relief. Surg Neurol Int. 2010;1:80.
37. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19(8):717-729.
38. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261.
39. Pollack RM, Barzilai N, Anghel V, *et al*. Resveratrol improves vascular function and mitochondrial number but not glucose metabolism in older adults. J Gerontol A Biol Sci Med Sci. 2017;72(12):1703-1709.
40. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999;12(4):564-582.
41. Sun D, Abraham SN, Beachey EH. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother. 1988;32(8):1274-1277.
42. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils--a review. Food Chem Toxicol. 2008;46(2):446-475.
43. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs *in vi*vo. Antimicrob Agents Chemother. 1997;41(7):1413-1422.
44. Gagnier JJ, Boon H, Rochon P, *et al*. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134-1149.
45. Kasper S, Caraci F, Forti B, *et al*. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 2010;20(11):747-765.